Paper Details

  1. Home
  2. Paper Details

Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.

Author: AlkhouriNaim, BashirMustafa, HarrisonStephen A, McCartyKevin, MoussaSam E, Pablo FriasJuan, TaubRebecca

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Resmetirom, a selective thyroid hormone receptor-β agonist, was evaluated for its efficacy and safety in patients with nonalcoholic steatohepatitis (NASH). In a 36-week open-label extension study, resmetirom significantly reduced liver fat, LDL cholesterol, apolipoprotein B, and triglycerides. It also reduced markers of fibrosis, suggesting a potential role in NASH treatment.
Paper Details　
Original Abstract of the Article :
Resmetirom (MGL-3196), a selective thyroid hormone receptor-β agonist, was evaluated in a 36-week paired liver biopsy study (NCT02912260) in adults with biopsy-confirmed nonalcoholic steatohepatitis (NASH). The primary endpoint was relative liver fat reduction as assessed by MRI-proton density ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034581/

データ提供：米国国立医学図書館（NLM）

Resmetirom: A New Oasis in the Desert of NASH Research?

Nonalcoholic steatohepatitis (NASH) is a growing public health concern, often leading to liver damage and fibrosis. This study, published in [Journal Name], investigates the efficacy and safety of resmetirom, a selective thyroid hormone receptor-beta agonist, for treating NASH. The researchers conducted a 36-week open-label extension (OLE) study in patients who had participated in a previous paired liver biopsy study. The study found that resmetirom significantly reduced liver fat, improved liver enzyme levels, and reduced markers of fibrosis, suggesting potential for this drug to manage NASH.

Resmetirom: A Potential Hope for NASH

This research suggests that resmetirom may be a promising new treatment for NASH. It's like finding a new oasis in the desert of NASH research, offering hope for patients struggling with this challenging condition.

NASH: A Desert of Challenges

NASH is a complex and multifaceted disease, and navigating this desert of challenges requires a comprehensive approach. Healthy lifestyle modifications, including diet, exercise, and weight management, are crucial. This study underscores the importance of ongoing research to develop effective treatments for NASH. Remember, healthy lifestyle choices can help you stay hydrated and thrive in the desert of health challenges.

Dr. Camel's Conclusion

This OLE study provides further evidence supporting the potential efficacy and safety of resmetirom for NASH. It's like finding a sustainable source of water in the vast desert of NASH, offering a potential solution for a growing health concern. While more research is needed to confirm its long-term impact, resmetirom holds promise for improving the lives of patients with NASH. Remember, a healthy lifestyle and a proactive approach to your health are essential for navigating the challenges of NASH.

Date :
  1. Date Completed 2021-12-24
  2. Date Revised 2023-03-08
Further Info :

Pubmed ID

33860116

DOI: Digital Object Identifier

PMC8034581

Related Literature

Article Analysis
・Effects of resmetirom
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.